Quick Answer: Ozempic for weight loss is not an FDA-labelled use. The Ozempic label covers blood sugar control in adults with type 2 diabetes, plus lower cardiovascular and kidney risk in some of them. The same drug, semaglutide, is approved for weight management as Wegovy at a higher 2.4 mg dose. Ozempic doses run from 0.25 mg to 2 mg once a week. In label trials, nausea affected 15.8% to 20.3% of people on 0.5 mg and 1 mg doses, versus 6.1% on placebo. Novo Nordisk listed self-pay prices from $349 a month in May 2026. Counterfeit pens have been found, so use a licensed pharmacy.
If you want a prescription weight-management option, ask about Wegovy as well. See our guide to medical weight loss and the older pill option, Alli weight loss pills.
Is Ozempic for Weight Loss Approved?
Not by name. The May 2026 FDA label lists three uses, all in adults with type 2 diabetes. These are better blood sugar control, fewer major cardiovascular events in people with heart disease, and better kidney and cardiovascular outcomes in people with chronic kidney disease. Weight loss is not an indication.
Wegovy is the weight-management product. The FDA approved it in June 2021 for adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition. In the UK, NICE recommends Wegovy, not Ozempic, through specialist NHS services. There, eligibility is a BMI of 35 or higher with a condition. A BMI of 30 to 34.9 needs referral. Treatment lasts up to two years.
Some clinicians prescribe medicines outside their label. If yours does, ask why and what monitoring they plan. Check your BMI and what it measures first.
| Feature | Ozempic | Wegovy |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| Main labelled use | Type 2 diabetes and related risk reduction | Chronic weight management with diet and activity |
| Weekly dose range | 0.25 mg to 2 mg | Raised over 16 to 20 weeks to 2.4 mg |
| Boxed warning | Thyroid C-cell tumours | Thyroid C-cell tumours |
| Weight result in FDA material | Not an Ozempic label claim | 12.4% versus placebo (adults without diabetes); 6.2% versus placebo (type 2 diabetes) |
Sources: FDA Ozempic label (revised May 2026), FDA Wegovy announcement and NICE.
Ozempic for Weight Loss Dose: The Weekly Schedule
| Step | Weekly dose | Rule from the label |
|---|---|---|
| 1 | 0.25 mg | Start here for 4 weeks |
| 2 | 0.5 mg | Then 0.5 mg once weekly |
| 3 | 1 mg | Only after at least 4 weeks on the current dose |
| 4 | 2 mg (maximum) | Only after at least 4 weeks on the current dose |
Inject once a week on the same day, at any time and with or without food. You can change the day if doses are more than 48 hours apart. Use the abdomen, thigh or upper arm. Never share a pen.
If you miss a dose, take it as soon as possible within 5 days. After 5 days, skip it and resume your schedule. Your prescriber sets the dose, so do not adjust it yourself. Doses are in milligrams, never grams.
Why Ozempic for Weight Loss Numbers Disagree
Three different things get blended online. First, the drug differs: Ozempic tops out at 2 mg, while Wegovy reaches 2.4 mg. Second, the people differ. FDA material reports 12.4% weight loss versus placebo in adults without diabetes and 6.2% in adults with type 2 diabetes. Third, the sources differ, because the side effect tables on the Ozempic label come from diabetes trials.
As a result, a headline such as 30 pounds in six months says little about you. Your dose, your starting weight, whether you have diabetes and how long you stay on treatment all change the outcome. Personal stories are not trial data.
Meanwhile, results depend on the rest of your routine. Pair treatment with balanced protein, carbs and fats and regular walking, and plan for the long term with weight maintenance habits.
Ozempic Side Effects: What the Label Trials Show
| Reaction | Placebo | 0.5 mg | 1 mg |
|---|---|---|---|
| Nausea | 6.1% | 15.8% | 20.3% |
| Vomiting | 2.3% | 5% | 9.2% |
| Diarrhoea | 1.9% | 8.5% | 8.8% |
| Abdominal pain | 4.6% | 7.3% | 5.7% |
| Constipation | 1.5% | 5% | 3.1% |
Source: FDA Ozempic label, placebo-controlled trials in adults with type 2 diabetes. Nausea and vomiting rise with dose. Vomiting nearly doubles from 0.5 mg to 1 mg.
Because vomiting and diarrhoea cause fluid loss, keep drinking. Dehydration can injure the kidneys, which the label lists as a warning. See our guide to how drinking water affects weight loss and the signs of kidney failure.
Ozempic for Weight Loss Warnings: Who Should Not Use It
The boxed warning concerns thyroid C-cell tumours seen in rodents. Ozempic is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. Other label warnings include pancreatitis, diabetic retinopathy complications, gallbladder disease and severe gastrointestinal reactions. They also include allergic reactions and low blood sugar when used with insulin or insulin-releasing drugs.
Get urgent advice for severe, persistent stomach pain, vision changes or signs of an allergic reaction. The label does not recommend Ozempic in severe gastroparesis, a condition where the stomach already empties slowly. Tell any anaesthetist you take it, because of the risk of pulmonary aspiration during sedation.
For pregnancy, the label says to stop Ozempic at least 2 months before a planned pregnancy. If you take insulin, read about diabetes medicines and weight. For other medicine effects on weight, see our weight gain guide.
Appetite-suppressing treatment can worsen restriction. If you have, or have had, an eating disorder, speak to a clinician first. In the US, contact the National Alliance for Eating Disorders or call or text 988. In the UK, Samaritans is on 116 123.
Ozempic Cost in 2026 and How to Avoid Fakes
Novo Nordisk’s May 2026 self-pay guide lists $349 a month for the 0.25 mg, 0.5 mg and 1 mg pens, and $499 for the 2 mg pen. New patients could pay $199 a month for two fills of the 0.25 mg or 0.5 mg pen through December 31, 2026. Prices change, so confirm before you buy.
Insurance often depends on the reason for the prescription. A plan may cover Ozempic for type 2 diabetes but not for weight management. Medicare readers can start with how Medicare parts work.
The FDA says compounded versions are not FDA approved and are not reviewed for safety or quality. It reports counterfeit Ozempic in the US supply chain and 990 adverse event reports for compounded semaglutide as of May 31, 2026. Use a prescription from your doctor, filled at a state-licensed pharmacy.
What the Evidence Says About Ozempic for Weight Loss Claims
| Claim | Where it stands | Reader guidance |
|---|---|---|
| Ozempic is approved for weight loss | Not supported | The label covers type 2 diabetes. Wegovy is the weight-management product. |
| Raise the dose by 1 gram if sugar stays high | Not supported | Doses are 0.25 to 2 mg, changed by your prescriber after at least 4 weeks. |
| It speeds up digestion | Not supported | The label does not recommend it in severe gastroparesis. |
| It has no negative side effects | Not supported | Nausea affected up to 20.3% of people in label trials. |
| Lowers heart attack and stroke risk | Supported for a defined group | Adults with type 2 diabetes and established cardiovascular disease. |
| A 2 mg pen costs $941 | Outdated | Self-pay listed at $499 for 2 mg in May 2026. |
| Personal reviews predict your result | Not supported | Trial averages are better guides, and results vary. |
Ozempic for Weight Loss FAQ
Ozempic is a once-weekly semaglutide injection. Its FDA label covers type 2 diabetes and related heart and kidney risk reduction in adults.
No. Weight loss is not an Ozempic indication. Semaglutide 2.4 mg is approved for weight management as Wegovy.
FDA material reports 12.4% versus placebo in adults without diabetes and 6.2% in adults with type 2 diabetes, using Wegovy. Individual results vary.
The label starts at 0.25 mg weekly for 4 weeks, then 0.5 mg. Later steps happen only after at least 4 weeks on the current dose, up to 2 mg.
Take it within 5 days. After more than 5 days, skip it and resume your usual day.
You can take it with or without meals, at any time of day. The label gives no list of foods to avoid.
Nausea, vomiting, diarrhoea, abdominal pain and constipation. Nausea affected 15.8% on 0.5 mg and 20.3% on 1 mg in label trials.
Novo Nordisk listed self-pay prices of $349 a month for 0.25, 0.5 and 1 mg pens and $499 for 2 mg in May 2026. Insurance terms vary.
No. The FDA says compounded drugs are not FDA approved and are not reviewed for safety, effectiveness or quality.
Related Reading
- Alli weight loss pills: side effects, dosing and safety
- Medical weight loss: what it involves
- Does insulin cause weight gain? Diabetes drugs compared
- Sustainable weight loss tips that last
Sources
- FDA: Ozempic (semaglutide) prescribing information, revised May 2026
- FDA: approval of Wegovy for chronic weight management, June 2021
- Novo Nordisk NovoCare: Ozempic price guide, May 2026
- FDA: concerns with unapproved GLP-1 drugs used for weight loss
- NICE: semaglutide for weight management in specialist NHS services
Written and fact-checked by the HealthCoachJP editorial team. No clinician has reviewed this article. See our sources cited page. Last reviewed and rewritten October 2026. Prices and eligibility reflect US and UK sources and can change.
Medical disclaimer: this article is general information, not medical advice. Do not start, stop or change prescribed medicine without your prescriber.
